{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:23:23Z","timestamp":1786116203869,"version":"build-2736575974"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immunocompromised patients have a risk of severe COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe the outcomes of ensitrelvir in hospitalized immunocompromised patients with COVID-19, with remdesivir as a reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Single-center retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed patients with moderate\/severe immunodeficiency who received ensitrelvir or remdesivir as initial therapy. The primary outcome was 28-day all-cause mortality; secondary outcomes were time to discharge and viral clearance. Exploratory analyses used inverse probability of treatment weighting (IPTW) based on propensity scores and Cox proportional-hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 56 patients (22 ensitrelvir; 34 remdesivir), 28-day mortality was 4.5% versus 8.8%, respectively. Time to discharge and viral clearance were similar. IPTW-adjusted 28-day mortality was 4.2% with ensitrelvir and 10.7% with remdesivir (hazard ratio 0.39; 95% CI 0.04\u20133.64).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this small, single-center exploratory cohort, ensitrelvir was associated with low mortality, although comparison with remdesivir should be interpreted cautiously given treatment selection, treatment switching, and limited sample size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361261464359","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:20:41Z","timestamp":1785835241000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study"],"prefix":"10.1177","volume":"13","author":[{"given":"Masaya","family":"Yamato","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1789-3641","authenticated-orcid":false,"given":"Masahiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Shionogi &amp; Co., Ltd., Grand Green Osaka South Building Park Tower, 5-54 Ofuka-Cho, Kita-Ku, Osaka 530-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Data Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Izuhara","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Rinku General Medical Center, Izumisano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[{"name":"Medical Science Department, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-03266-6"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0485-22"},{"key":"e_1_3_4_5_2","article-title":"Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review","volume":"12","author":"Mukae H","year":"2025","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, et al. Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review. Ther Adv Infect Dis 2025; 12: 20499361251321724.","journal-title":"Ther Adv Infect Dis"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01309-z"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01156-9"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_4_9_2","unstructured":"National Institute of Infectious Diseases Japan. Clinical guidelines for COVID-19 response in immunocompromised patients Ver. 1.0. 2023. https:\/\/id-info.jihs.go.jp\/surveillance\/iasr\/covid19-rinsyoutaiou.pdf (2023 accessed July 23 2025)."},{"key":"e_1_3_4_10_2","unstructured":"Ministry of Health Labour and Welfare Japan. New Coronavirus Infectious Disease (COVID-19) Medical Treatment Guide Version 10.1. Treatment guideline of COVID-19. https:\/\/www.mhlw.go.jp\/content\/001248424.pdf (2024 accessed July 23 2025)."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1515\/dx-2022-0021"},{"key":"e_1_3_4_12_2","first-page":"250","article-title":"Negative confirmation and infectivity estimation by quantitative antigen test of COVID-19 (Japanese)","volume":"71","author":"Kase F","year":"2022","unstructured":"Kase F, Ota T, Ota H, et al. Negative confirmation and infectivity estimation by quantitative antigen test of COVID-19 (Japanese). Jpn J Med Technol 2022; 71: 250\u2013256.","journal-title":"Jpn J Med Technol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09633-1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae510"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01504-9"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102805"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361261464359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361261464359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361261464359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T08:16:23Z","timestamp":1786004183000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361261464359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"alternative-id":["10.1177\/20499361261464359"],"URL":"https:\/\/doi.org\/10.1177\/20499361261464359","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20499361261464359"}}